Figure 5. Growth of combination resistant (CR) cell lines is inhibited significantly by adding everolimus and XAV939 in the presence of SU11274 and erlotinib.

Cells were treated for 96% growth inhibition was observed when everolimus was used with both SU11274 and erlotinib. B. Parental H2170 cells show little or no inhibition when given increasing concentrations of XAV939. Conversely, CR H2170 cells when treated with XAV939, were inhibited in a dose responsive manner. H2170 CR cells showing 40% inhibition to Wnt antagonist XAV939 (10 µM) alone, showed an 85% inhibition with triple combination of XAV939, SU11274 and erlotinib (p<0.01). Each experiment for each treatment condition was repeated three times.